A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF.

Study Question: Does an individualized serum anti-Müllerian hormone (AMH) based FSH dosing algorithm used in a GnRH antagonist protocol increase the proportion of patients with an intended number of oocytes (5-14) retrieved compared with a standard regimen?

Summary Answer: The AMH-based individualized algorithm did not increase the proportion of patients with an intended oocyte retrieval.

What Is Known Already: Individualizing treatment for ovarian stimulation by serum AMH or antral follicle count can theoretically improve the ratio between benefits and risks. Current data suggest that there may be a reduced risk of ovarian hyperstimulation syndrome (OHSS), but without improved pregnancy or live birth rates.